Metsigletic

Metformin Hydrochloride, the active ingredient in Metsigletic, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It helps control blood glucose in adults with type 2 diabetes mellitus, often in combination with diet and exercise.

GNH USA supplies Metsigletic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets, and ensures reliable batch release, traceability, and on‑time delivery to meet the needs of healthcare providers.

Metsigletic, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder.

- Type 2 diabetes mellitus (initial therapy): improves overall glycemic control when diet, exercise, and metformin alone are insufficient. - Type 2 diabetes mellitus (add‑on therapy): provides additional glucose‑lowering effect when combined with other oral antidiabetic agents. - Type 2 diabetes mellitus (post‑prandial control): enhances insulin secretion to better manage post‑prandial glucose excursions.

Metsigletic may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate. - Nasopharyngitis: upper respiratory symptoms. - Dizziness: light‑headed feeling.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, angioedema, or anaphylaxis. - Renal impairment worsening: accumulation of metformin.

Before prescribing Metsigletic, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR to ensure metformin clearance. - Hepatic function monitoring: check liver enzymes for potential dysfunction. - Cardiovascular status: avoid in patients with unstable or severe heart failure. - Elderly patients: start at lower doses and monitor for lactic acidosis. - Concomitant hypoglycemics: adjust doses to reduce risk of severe hypoglycemia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metsigletic can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing metformin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise sitagliptin levels, heightening risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal function, necessitating dose adjustment. - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - Alcohol: increases risk of lactic acidosis. - NSAIDs: may impair renal clearance, requiring periodic renal monitoring.